Equibles does not estimate personal net worth.
Get an email with a short summary when Sera Prognostics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SERA alertsAustin Aerts is recorded as CFO at Sera Prognostics, Inc. (SERA) since June 7, 2023. Sera Prognostics, Inc. reported in an 8-K filed August 19, 2026 that Austin Aerts was terminated as Chief Financial Officer, effective September 8, 2026. Sera Prognostics, Inc. reported in an 8-K filed May 25, 2023 that Austin Aerts was appointed interim Chief Financial Officer, effective June 7, 2023. The proxy statement of Sera Prognostics, Inc. reports total compensation of $1,035,998 for Austin Aerts in fiscal 2023, including a base salary of $307,627. Disclosed compensation is on record for 2 fiscal years. Austin Aerts has spoken on 12 earnings calls across 1 company, most recently for Sera Prognostics, Inc. on August 12, 2026. Sera Prognostics, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Sera Prognostics, Inc. includes Zhenya Lindgardt (CEO and Board Member), Kim Kamdar, Ph.D. (Chairman), Scott Gleason (CFO) and 7 others.
“WHEREAS, Consultant's employment under such Employment Agreement is terminated as of the Effective Date;”
“Concurrently with Mr. Moyes’s resignation, Austin Aerts, the Company’s current Vice President of Finance and Corporate Controller, was appointed as the interim Chief Financial Officer of the Company, effective June 7, 2023.”
“Revenue for the quarter was $30,000 compared to $17,000 in the second quarter of 2025. As expected, revenue in the quarter remained modest, reflecting the timing and nature of our geographically targeted commercialization strategy and our ongoing effort to build advocacy and awareness following the Prime publication.”
“Revenue for the quarter was $14,000 compared to $38,000 in the first quarter of 2025. As expected, revenue in the quarter remained modest, reflecting the timing and nature of our geographically targeted commercialization strategy and our ongoing effort to build advocacy and awareness following the PRIME publication.”
“I'll start with our financial results and then discuss our cash runway and capital allocation philosophy. Starting with the fourth quarter, revenue for the quarter was $10,000 compared to $24,000 in the fourth quarter of 2024.”
“I'll provide an overview of our financial performance for the third quarter of 2025 and our balance sheet position. Net revenue for the third quarter was $16,000 compared to $29,000 in the same period last year.”
“Let me review our financial results for the second quarter. Net revenue for the second quarter of 2025 was $17,000 compared to $24,000 for the second quarter of 2024.”
2023-06-07–present
Start not stated–2026-09-08
Medical Devices · Healthcare
CFO
2023-06-07–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Sera Prognostics, Inc. (SERA) | Chief Financial Officer | $307,627 | $1,035,998 |
| 2022 | Sera Prognostics, Inc. (SERA) | Chief Financial Officer | $230,150 | $389,448 |
